Metrics as of 10/13/2026, 08:45 AM (Berlin time), refresh in progress.
Rhythm Pharmaceuticals Stock
Rhythm Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David Meeker
- Employees
- 414
- Market cap
- $6 B
- IPO
- 09/10/2017
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company in the healthcare sector and biotechnology industry, headquartered in Boston, US. The company focuses on the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical product,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Rhythm Pharmaceuticals stock: price history
1D
-2.6%
1W
-3.6%
1M
-16.4%
6M
+0.3%
YTD
-18.2%
1Y
-13.1%
2Y
+75.7%
5Y
+661.0%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~38% stronger price swings than usual
Ask the agents about Rhythm Pharmaceuticals
Analyst assessment of Rhythm Pharmaceuticals
PRICE TARGET LOW
US$120.00
CONSENSUS
US$144.43
MEDIAN
US$154.00
PRICE TARGET HIGH
US$160.00
0
STRONG BUY
22
BUY
0
HOLD
0
SELL
0
STRONG SELL
22
TOTAL · Buy
As of: 12/10/2026
Rhythm Pharmaceuticals stock metrics
P/E
-28.19
P/B
27.67
EV/EBITDA
-32.22
RETURN ON EQUITY
-22.7%
NET MARGIN
-69.2%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.5%
FLOAT SHARES
55,931,300
AVG. DAILY VOLUME (30D)
706,965
Insider transactions (SEC)
Meeker David P
Meeker David P
Meeker David P
Meeker David P
Meeker David P
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.6%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Rhythm Pharmaceuticals stock
What does Rhythm Pharmaceuticals do?
Rhythm Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David Meeker, the company employs around 414 people.
The IPO was on 09/10/2017; the stock trades on NASDAQ under the ticker RYTM.
What do analysts say about Rhythm Pharmaceuticals stock?
22 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$144.43, ranging from US$120.00 to US$160.00, with a median of US$154.00.
This is an external assessment, not a statement by Market Jury.
When does Rhythm Pharmaceuticals report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 38% stronger than usual.
Does Rhythm Pharmaceuticals pay a dividend?
No, Rhythm Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Rhythm Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Rhythm Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Rhythm Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.